Investor Relations (IR) Questions: Dynavax Technologies DVAX
Click here to return to the biotech IRQ Index
Answers received: January 2013
1) When is the last time DVAX raised cash through an offering (diluted)? May 2012
2) How much cash (not cash equivalents) does DVAX have? As of the end of the third quarter, we had $148 million.
3) What and approximately when is the next known catalyst? February 24, 2012 is the FDA’s PDUFA date for our first product, HEPLISAV
4) What is DVAX's quarterly cash burn? Approximately $15 million
5) Does DVAX have an existing line of credit and if so how much can they draw against it? No
1) When is the last time DVAX raised cash through an offering (diluted)? May 2012
2) How much cash (not cash equivalents) does DVAX have? As of the end of the third quarter, we had $148 million.
3) What and approximately when is the next known catalyst? February 24, 2012 is the FDA’s PDUFA date for our first product, HEPLISAV
4) What is DVAX's quarterly cash burn? Approximately $15 million
5) Does DVAX have an existing line of credit and if so how much can they draw against it? No
Bonus resource - slide deck from 2013 JP Morgan Healthcare Conference |
|